Agent
Olpasiran (AMG 890)
Status Phase 3 outcomes (OCEAN(a)-Outcomes, n=7,297) and primary prevention (OCEAN(a)-PreEvent, n=11,000)
A GalNAc-conjugated small interfering RNA that degrades LPA mRNA, given 75 mg subcutaneously every 12 weeks. Lowered Lp(a) by more than 95 percent in OCEAN(a)-DOSE (NEJM 2022) with a long off-treatment tail (JACC 2024). OCEAN(a)-Outcomes started December 2022 with a readout pointed at 2026 to 2027; OCEAN(a)-PreEvent, the first primary-prevention Lp(a) outcomes trial, started August 2025.
Mechanism. Double-stranded siRNA loaded into RISC in hepatocytes; catalytic, hence quarterly dosing.
Milestones. Preclinical and phase 1 (Koren, Nat Med 2022); OCEAN(a)-DOSE (O'Donoghue, NEJM 2022) and extension (JACC 2024); OxPL and inflammatory-marker substudy (JAMA Cardiol 2025); OCEAN(a)-Coronary imaging study started 2026.
olpasiranRNA therapeuticssiRNA
Page updated 17 August 2026.